Sugi Predict

Sugi Predict / Compounds / SCHEMBL1151099

SCHEMBL1151099

SCHEMBL1151099

Cn1ccn2c(=O)c(O)c(-c3ncc(Cc4ccc(Cl)cc4)s3)nc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRHBP P24387 1/20 0.40
▸ CRHR2 Q13324 1/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ FFAR2 O15552 1/20 0.36
▸ SIRT2 Q8IXJ6 1/20 0.36
▸ HSD17B13 Q7Z5P4 4/20 0.36
▸ ABL1 P00519 1/20 0.35
▸ MAPT P10636 1/20 0.34
▸ ALOX5 P09917 1/20 0.34
▸ ENPP2 Q13822 1/20 0.34
▸ PIK3CD O00329 1/20 0.33
▸ PIK3CB P42338 1/20 0.33
▸ PTGDR2 Q9Y5Y4 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1150957 0.90 SMN1; SMN2 (0.40) MEN1KMT2AHSD17B13ABL1PIK3CD
SCHEMBL1151264 0.89 SMN1; SMN2 (0.39) HSD17B13MAPTPIK3CDPIK3CBALDH1A1
SCHEMBL12862295 0.89 PIK3CD (0.39) HSD17B13PIK3CDPIK3CBCYP3A4
SCHEMBL1150831 0.87 HSD17B13 (0.36) HSD17B13PIK3CDPIK3CB
SCHEMBL12861854 0.82 EGFR (0.37) CRHBPCRHR2MEN1KMT2AL3MBTL1
SCHEMBL1360972 0.81 MAPT (0.42) CRHBPCRHR2MEN1KMT2AL3MBTL1
SCHEMBL1220959 0.78 SLC2A1 (0.50) MAPTALOX5PIK3CDPIK3CBTSHR
SCHEMBL12874954 0.74 NPSR1 (0.36) MEN1KMT2AABL1ALDH1A1
SCHEMBL12874724 0.74 HSP90AA1 (0.35) HSD17B13MAPTPIK3CDPIK3CBALDH1A1
SCHEMBL1151035 0.74 SMN1; SMN2 (0.35) MEN1KMT2AHSD17B13ABL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 — — US disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 — — US disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 — — US disclosed
EP-2291377-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF Avexa Limited (AU) 2011-03-09 — — EP disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 — — US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 — — US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 — — US disclosed
WO-2010000031-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 — — WO disclosed
WO-2010000031-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF TPMT, DPYD, IMPDH1 CRHBP 4206/4885CRHR2 3794/4885MEN1 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.